"The voice for cancer physicians and their patients in Massachusetts."

FDA Approves emicizumab-kxwh for patients with hemophilia A with factor VIII inhibitors

17 Nov 2017 7:39 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved emicizumab-kxwh (Hemlibra; Genentech) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congential factor VIII deficiency) with factor VIII inhibitors. Read full press release. 

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software